These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 39167870)

  • 1. Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure-activity relationship.
    Pal R; Matada GSP; Teli G; Saha M; Patel R
    Bioorg Chem; 2024 Nov; 152():107696. PubMed ID: 39167870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Update on JAK Inhibitors.
    Musumeci F; Greco C; Giacchello I; Fallacara AL; Ibrahim MM; Grossi G; Brullo C; Schenone S
    Curr Med Chem; 2019; 26(10):1806-1832. PubMed ID: 29589523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RuBi-Ruxolitinib: A Photoreleasable Antitumor JAK Inhibitor.
    Rafic E; Ma C; Shih BB; Miller H; Yuste R; Palomero T; Etchenique R
    J Am Chem Soc; 2024 May; 146(19):13317-13325. PubMed ID: 38700457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy.
    Wu C; Zhang L; Zhou Z; Tan L; Wang Z; Guo C; Wang Y
    Eur J Med Chem; 2024 Oct; 276():116649. PubMed ID: 38972078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
    Arafa RK; Nour MS; El-Sayed NA
    Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines.
    Kilic-Kurt Z; Bakar-Ates F; Karakas B; Kütük Ö
    Anticancer Agents Med Chem; 2018; 18(9):1303-1312. PubMed ID: 29866023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment.
    Dubey R; Makhija R; Sharma A; Sahu A; Asati V
    Bioorg Chem; 2024 Aug; 149():107508. PubMed ID: 38850781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, Characterization, Antimicrobial Activity and Anticancer of Some New Pyrazolo[1,5-a]pyrimidines and Pyrazolo[5,1-c]1,2,4-triazines.
    Hosny MA; Zaki YH; Mokbel WA; Abdelhamid AO
    Med Chem; 2020; 16(6):750-760. PubMed ID: 31218963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.
    Singaram K; Marimuthu D; Baskaran S; Chinaga SK; Shanmugarajan D; Vadivel T
    Comb Chem High Throughput Screen; 2017; 20(8):703-712. PubMed ID: 28738766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates.
    Coricello A; Mesiti F; Lupia A; Maruca A; Alcaro S
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32707925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New C2- and N3-Modified Thieno[2,3-d]Pyrimidine Conjugates with Cytotoxicity in the Nanomolar Range.
    Mavrova AT; Dimov S; Yancheva D; Rangelov M; Wesselinova D; Naydenova E
    Anticancer Agents Med Chem; 2022; 22(6):1201-1212. PubMed ID: 34315388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors.
    Zheng YG; Wang JA; Meng L; Pei X; Zhang L; An L; Li CL; Miao YL
    Eur J Med Chem; 2021 Jan; 209():112934. PubMed ID: 33109396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Novel Pyrrolo[2,3-
    Liang X; Tang S; Liu X; Liu Y; Xu Q; Wang X; Saidahmatov A; Li C; Wang J; Zhou Y; Zhang Y; Geng M; Huang M; Liu H
    J Med Chem; 2022 Jan; 65(2):1243-1264. PubMed ID: 33586434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors.
    Shu L; Chen C; Huan X; Huang H; Wang M; Zhang J; Yan Y; Liu J; Zhang T; Zhang D
    Eur J Med Chem; 2020 Apr; 191():112148. PubMed ID: 32097841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
    Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
    Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure-activity relationship studies of 1,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 1 (JAK1) inhibitors.
    Kim W; Lee SM; Jeong PH; Jung JH; Kim YC
    Bioorg Med Chem Lett; 2022 Jan; 55():128451. PubMed ID: 34774741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
    Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.